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Background/Aims: Adenosine is an endogenous modu-
lator of nociception. Its role in visceral nociception, 
particularly in visceral hyperalgesia, has not been stu-
died. The aim of this study was to determine the ef-
fects of adenosine receptor agonists in a model of 
visceral hyperalgesia. Methods: The visceromotor re-
sponse (VMR) in rats to colorectal distension (CRD; 
80 mmHg, 20 seconds) was quantified by electromyo-
graphic recordings from the abdominal musculature. 
Three hours after the intracolonic administration of zy-
mosan (25 mg/mL, 1 mL), VMRs to CRD were meas-
ured before and after either subcutaneous or intra-
thecal administration of an adenosine receptor agonist. 
Results: Subcutaneous injection of 5'-N-ethylcarboxy-
amidoadenosine (NECA; an A1 and A2 receptor ago-
nist), R(-)-N6-(2-phenylisopropyl)-adenosine (R-PIA; a 
selective A1 receptor agonist), or CGS-21680 hydro-
chloride (a selective A2a receptor agonist) dose-dep-
endently (10-100 mg/kg) attenuated the VMR to CRD, 
although hindlimb weakness occurred at the higher 
doses tested. Intrathecal administration of NECA or 
R-PIA dose-dependently (0.1-1.0μg/kg) decreased the 
VMR, whereas CGS-21680 hydrochloride was inef-
fective over the same concentration range. Higher in-
trathecal doses of the A1/A2 receptor agonist NECA 
produced motor weakness. Conclusions: Adenosine re-
ceptor agonists are antihyperalgesic, but also produce 
motor weakness at high doses. However, activation of 
the spinal A1 receptor significantly attenuates the 
VMR to CRD without producing motor weakness. (Gut 
and Liver 2008;2:39-46)
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INTRODUCTION
  Adenosine has been known as one of the neuro-
transmitter and it exerts multiple influences on pain 
transmission. Several previous studies already proved 
there is an endogenous adenosine in the peripheral nerve 
ending and spinal cord.1,2 The endogenous compound of 
adenosine is present in all cells. It may be released from 
cells directly or via degradation of ATP and is involved in 
many regulatory mechanisms both in physiological and 
pathophysiological conditions.3,4 It affects both sensory 
and motor neuron. It acts as an endogenous moduator of 
nociception. Because of its potential as a new analgesic, 
interests in adenosine are increasing among physicians 
and pharmacologists. The various pain modulating effects 
of adenosine and its analogs in animal models has been 
known for more than 10 years. Adenosine has effects in 
peripheral and central nervous system, mediated through 
specific cell surface associated receptors. With the devel-
opment of selective adenosine agonists and antagonists, 
its role in pain perception is being elucidated. 
  Adenosine receptors are found in the peripheral nerve 
ending and spinal cord. Adenosine has been suggested to 
have both pre- and postsynaptic effects within the dorsal 
horn indicating possible multiple sites of action of ad-
enosine in the control of sensory events related to pain. 
Adenosine shows variable influences on pain transmission 
at peripheral and spinal sites according to its receptor.5 
Adenosine A1 receptor activation in rodents, produces an-
tinociception at peripheral nerve terminals and spinal 
cord level in somatic pain model. Activation of adenosine 
A2 receptor (A2a, A2b) exerts multiple responses accord-
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ing to the concentration that was administrated and the 
site of action. At the peripheral nerve endings in rodents, 
adenosine A2 receptor activation is known to induce pro-
nociceptive or pain enhancing properties. However, in the 
spinal cord, adenosine A2 receptor activation at lower 
doses reduces pain perception and at higher doses it 
causes motor weakness.
  All those findings were observed in somatic pain mod-
els, such as acute nociceptive, inflammatory or neuro-
pathic pain model. Its role in visceral nociception, and 
particularly visceral hyperalgesia, has not been studied. 
However, experimental and clinical data are pointing at 
the adenosine system as an interesting target in relation 
to hypersensitivity states. The aim of this study was to 
evaluate the effects of adenosine receptor agonists in a 
model of visceral hyperalgesia.
MATERIALS AND METHODS
1. Animals
  Adult male Sprague-Dawley rats (400-425 g; Harlan, In-
dianapolis, IN) were used. Rats were housed one per cage 
in the animal care facility at the university of Iowa 
(approved by the American Association for Accreditation 
of Laboratory Animal Care), allowed free access to food 
and water, and maintained on a 12-hour light-dark cycle 
(lights on between 6 am and 6 pm). All experimental 
procedures were approved by the Institutional Animal 
Care and Use Committee at the University of Iowa.
2. Surgical Preparation
  The procedure was described earlier.6 Rats were deeply 
anesthetized with pentobarbital sodium (45 mg/kg, Nem-
butal; Abbott Laboratories, North Chicago, IL) admini-
stered intraperitoneally. Electrodes (Teflon-coated stain-
less steel wire; Cooner Wire Sales, Chatworth, CA) were 
stitched into the external oblique musculature, just supe-
rior to the inguinal ligament, for electromyographic 
(EMG) recording. The electrode leads were tunneled sub-
cutaneously and exteriorized at the nape of the neck for 
future access. An intrathecal catheter (polyethylene 10 tu-
bing, 8.5 cm long) was inserted through the dura over-
lying the atlanto-occipital junction into the spinal sub-
arachnoid space and guided to the lumbar enlargement. 
The catheter was surgically anchored to the musculature 
at the back of the neck and externalized with EMG leads. 
Animals exhibiting motor deficits after surgery due to 
spinal cord injury during intrathecal catheter insertion 
were not used. After surgery, rats were housed separately 
and allowed to recuperate for at least 7 days before 
testing. At the end of the experiments, rats were killed 
with an overdose of intraperitoneal pentobarbital.
3. Behavioral Testing
  The stimulus used has been described previously.7,8 The 
descending colon and rectum were distended by pres-
sure-controlled air inflation of a 6-7-cm-long, 2-3-cm di-
ameter, flaccid, flexible latex balloon tied around a flexi-
ble tube (Tygon). The balloon was lubricated (Surgilube; 
E. Fougera & Co., Melville, NY), inserted into the colon 
via the anus, and anchored by taping the balloon catheter 
to the base of the tail. Noxious phasic CRD (80 mm Hg, 
20 seconds, 5 minutes apart) were achieved by opening a 
solenoid gate to a constant pressure air reservoir. Intraco-
lonic pressure was continuously monitored with the aid 
of a pressure control device (Bioengineering, University of 
Iowa, Iowa city, IA). The response quantified was the 
VMR, a contraction of the abdominal and hindlimb 
musculature. EMG activity produced by contraction of the 
external oblique musculature was quantified by recording 
the number of discharges crossing a preset voltage thre-
shold (baseline). Each distention trial lasted 40 seconds, 
and EMG activity was quantified in 1-second bins for 10 
seconds before distention, 20 seconds during distention, 
and 10 seconds after distention. The increase in total 
number of recorded counts during distention (above base-
line) was defined as the response.
4. Drugs
  Because adenosine is rapidly metabolized by endothe-
lium within 10 seconds when administered systemically, 
we used adenosine analogues. Drugs used were 5'-N-eth-
ylcarboxyamidoadenosine (NECA), an A1 and A2 receptor 
agonist, R(-)-N6-(2-phenylisopropyl)-adenosine (R-PIA), a 
selective A1 receptor agonist, or CGS-21680 hydrochlo-
ride (CGS 21680), a selective A2a receptor agonist. Stock 
solutions were freshly prepared by dissolving the drugs in 
dimethyl sulfoxide solution and followed by adding sterile 
preservative-free saline. 
5. Experimental Protocol
  On the day of testing, four stable control responses to 
CRD (80 mm Hg, 20 seconds, 5 minutes apart) were ob-
tained in conscious, unsedated rats before any treatment. 
And then, while the animals were briefly anesthetized 
with halothane, zymosan (25 mg/mL, 1 mL; Sigma Che-
mical Co., St. Louis, MO), was instilled into the colon 
through a gavage needle inserted into the colon to a 
depth of about 7-8 cm. Three hours after intracolonic 
treatment, four control responses to CRD were obtained 
to establish whether rats were hyperalgesic (i.e., gave sig-
nificantly increased responses to 80 mm Hg CRD). Two 
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Fig. 1. Effect of subcutaneous administration of NECA on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis
(B). Subcutaneous injection of NECA attenuated VMR to CRD dose dependently. At low dose (10 mg), NECA slightly decreases
VMR to CRD. However, at higher doses (30, 100 mg), NECA markedly decreases VMR to CRD with the development of motor 
weakness (*p＜0.05). 
NECA, 5-N-ethylcarboxyamidoadenosine; VMR, visceromotor response; CRD, colorectal distension.
minutes after these distension, drug (or vehicle) was ad-
ministered systemically through subcutaneous injection or 
inthrathecally to the lumbar enlargement through the in-
dwelling catheter. All drugs that administered systemi-
cally were in a volume of 0.1 mL/100 g of rat body 
weight, and all drugs that administered intrathecally were 
in a volume of 5μL followed by a flush with 10μL of 
sterile, preservative-free saline over a period of 1 minute. 
The progress of the injection was continuously monitored 
by following the movement of an air bubble in the 
tubing. Absence of drug leakage during injection was also 
confirmed. Dose-response curves were generated using a 
cumulative dosing paradigm. The first intrathecal injec-
tion was made 2 minutes after documenting the presence 
of hyperalgesia. Subsequent doses of drugs were injected 
20 minutes apart, thus allowing four distentions after 
each dose of drug. Data were reported as the average re-
sponse to the four distentions. Because there was no 
change in VMR to CRD in group of animals that received 
saline subcutaneously or intrathecally, these data were 
pooled (vehicle).
6. Data Analysis
  Data were represented as mean±SEM. Data for VMRs 
were normalized as percentage of control, calculated as 
percent of mean of four responses to CRD obtained in 
the same animal. Baseline VMR, VMR 3 hour after intra-
colonic zymosan instillation, and VMR after subcuta-
neously or intrathecal drug injections were compared. 
Changes in VMR after drug administration were statisti-
cally analized by repeated-measures analysis of variance 
(ANOVA), one-way ANOVA followed by the Student 
modified t test with the Bonferroni correction for multi-
ple comparisons. p values of ＜0.05 were considered stat-
istically significant in all tests.
RESULTS
1. Effect of Subcutaneous Administration of Ade-
nosine Agonists and Antagonist on Zymosan- 
Induced Visceral Hyperalgesia
  All experimental groups consisted of at least 6-8 
animals. All the animals became hyperalgesic after intra-
colonic instillation of zymosan. The overall mean increase 
in the VMR three hours after intracolonic instillation of 
zymosan was 124±6% compared to that of baseline.
  In this series of experiments, effects of adenosine ago-
nists were evaluated at variable doses (10, 30, 100 mg). 
Subcutaneous injection of 5'-N-ethylcarboxyamidoadeno-
sine (NECA), an A1 and A2 receptor agonist, 3 hours af-
ter intracolonic treatment with zymosan attenuated VMR 
to CRD dose dependently (p＜0.05). At low dose (10 
mg), NECA slightly decreased VMR to CRD without mo-
tor weakness compared to response after vehicle admini-
stration. VMR to CRD was average only 90% of baseline 
and that meant mild analgesic effect. However, at higher 
doses (30, 100 mg), NECA markedly decreased VMR to 
CRD with the development of motor weakness (Fig. 1). 
VMR to CRD was less than 10% of baseline at 100 mg. 
Hindlimb became flaccid and rat could not move with 
hindlimb, but it was recovered later completely. The ef-
fect of NECA on zymosan-produced visceral hyperalgesia 
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Fig. 2. Effect of subcutaneous administration of R-PIA on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis 
(B). R-PIA does not attenuated VMR to CRD at dose of 10 mg and 30 mg. At 100 mg, R-PIA decreases VMR to CRD without 
development of motor weakness (*p＜0.05).
R-PIA, R(-)-N6-(2-phenylisopropyl)-adenosine; VMR, visceromotor response; CRD, colorectal distension.
Fig. 3. Effect of subcutaneous administration of CGS-21680 on zymosan-induced visceral hyperalgesia (A) and result of statistical 
analysis (B). CGS-21680 attenuates VMR to CRD at doses of 30 mg and 100 mg (p＜0.05) but not at 10 mg. At high dose, 
hindlimb weakness is produced (*p＜0.05).
VMR, visceromotor response; CRD, colorectal distension.
was fast (5 minutes after administration) and last more 
than 20 minutes. 
  Subcutaneous administration of R(-)-N6-(2-phenyliso-
propyl)-adenosine, (R-PIA), a selective A1 receptor ago-
nist, did not attenuated VMR to CRD at doses of 10 and 
30 mg. At higher dose (100 mg), R-PIA decreased VMR 
to CRD (p＜0.05) without development of motor weak-
ness (Fig. 2). VMR to CRD was less than 80% of base 
line.
  CGS-21680 hydrochloride (CGS 21680), a selective A2a 
receptor agonist, attenuated VMR to CRD at doses of 30 
mg and 100 mg (p＜0.05) but not at 10 mg (Fig. 3). At 
the higher dose (100 mg), hindlimb weakness was pro-
duced, but it was also recovered completely.
2. Effect of Subcutaneous Administration of Ade-
nosine Antagonist on Zymosan-Induced Visce-
ral Hyperalgesia
  8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), a selective 
A1 receptor antagonist was administered subcutaneously 
at a dose 100 mg 5 minutes before the subcutaneous ad-
ministration of R-PIA. Even though effective dose of 
R-PIA (100 mg) was injected, DPCPX prevented the de-
crease in VMR to CRD by R-PIA (Fig. 4). Furthermore, 
there was no evidence of pain facilitation or side effect. 
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Fig. 4. Effect of subcutaneous administration of DPCPX on 
zymosan-induced visceral hyperalgesia. DPCPX, when injected 
subcutaneously 5 minutes before the subcutaneous admini-
stration of R-PIA, prevents the decrease in VMR to CRD by 
R-PIA.
DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; R-PIA, R(-)-N6- 
(2-phenylisopropyl)-adenosine; VMR, visceromotor response; 
CRD, colorectal distension.
Fig. 5. Effect of intrathecal administration of NECA on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis
(B). NECA attenuates VMR to CRD at dose of 0.3μg and 1.0μg (p＜0.05) but not at 0.1μg. Both 0.3μg, 1.0μg of NECA 
produces motor weakness (*p＜0.05).
NECA, 5-N-ethylcarboxyamidoadenosine; VMR, visceromotor response; CRD, colorectal distension.
3. Effect of Intrathecal Administration of Adenosine 
Agonists on Zymosan-Induced Visceral Hyperal-
gesia
  Effects of intrathecal adenosine agonists were inves-
tigated at variable doses (0.1, 0.3, 1.0μg). Intrathecal ad-
ministration of NECA attenuated VMR to CRD at dose of 
0.3μg and 1.0μg (p＜0.05) but not at 0.1μg. Both 0.3
μg, 1.0μg of NECA produced motor weakness (Fig. 5). 
Flaccidity of hindlimb disappeared later completely. 
  Intrthecal administration of R-PIA at doses of 0.1μg 
did not induce decrease in VMR to CRD. However, 0.3μg 
and 1.0μg of intrathecal R-PIA produced decrease in 
VMR to CRD (p＜0.05) without development of motor 
weakness (Fig. 6). 
  Intrthecal CGS 21680 administration (0.1-1.0μg) was 
ineffective. Higher dose of CGS 21680 (3.0μg) showed 
mild decrease in VMR to CRD (Fig. 7). 
4. Effect of Intrathecal Administration of Adenosine 
Antagonist on Zymosan-Induced Visceral Hyper-
algesia
  DPCPX, was administered intrathecally at a dose 1μg 
5 minutes before the intrathecal administration of R-PIA. 
Even though effective dose of R-PIA (1μg) was injected 
intrathecally, DPCPX also prevented the decrease in VMR 
to CRD by intrathecal R-PIA (Fig. 8). 
DISCUSSION
  This study showed that adenosine can modulate viscer-
al hyperalgesia. Several animal studies have shown that 
adenosine or adenosine analogues have important roles in 
the control of nociception4,5 and they may have a poten-
tial role in treatment of pain in humans.9,10 The most in-
teresting was the potential to modulate the pathological 
states, such as hyperexcitability associated with injuries 
to the peripheral and central nervous systems. Adenosine 
was effective to decrease pain perception in neuropathic 
pain model created by ligation of nerve in rats.11,12 Clini-
cally adenosine became a new candidate of analgesic for 
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Fig. 6. Effect of intrathecal administration of R-PIA on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis 
(B). R-PIA at doses of 0.1μg does not induce decrease in VMR to CRD. However, 0.3μg and 1.0μg of intrathecal R-PIA produces 
decrease in VMR to CRD without development of motor weakness (*p＜0.05).
R-PIA, R(-)-N6-(2-phenylisopropyl)-adenosine; VMR, visceromotor response; CRD, colorectal distension.
Fig. 7. Effect of intrathecal administration of CGS 21680 on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis 
(B). CGS 21680 (0.1-1.0μg) is ineffective. Only higher dose of CGS 21680 (3.0μg) shows slight decrease in VMR to CRD.
VMR, visceromotor response; CRD, colorectal distension.
the treatment of patients with neuropathic pain.13-15 This 
study was performed in visceral hypersensitivity model 
and the results revealed adenosine and its analogues can 
have important role in the treatment of functional gastro-
intestinal disorders. Furthermore, there is an evidence of 
pain relief by adenosine in patients with noncardiac chest 
pain.16 
  As mentioned earlier, adenosine has at least two kinds 
of receptor, A1 and A2 receptor. At peripheral nerve ter-
minals in rodents, adenosine A1 receptor activation by di-
rect local administration of adenosine A1 receptor agonist 
produces antinociception, while adenosine A2 receptor ac-
tivation produces pronociceptive or pain enhancing pro-
perties.5 In the spinal cord, recent studies using more se-
lective agonists and antagonists have implicated primarily 
A1 receptor in antinociception and A2 receptor in muscle 
relaxation.17,18 For both receptor subtypes, dorsal spinal 
cord levels exceed ventral spinal cord level, and adenosine 
A1 receptors are selectively concentrated in the substantia 
gelatinosa.19-22 In our study, antihyperalgesic and analgesic 
effect of adenosine upon visceral pain was mainly medi-
ated via A1 receptor. Systemic administration of A1 re-
ceptor agonist decreased VMR to CRD. Furthermore, 
even systemic administration of A2a agonist showed de-
creased VMR rather than increased VMR. But decrease in 
VMR after systemic administration of A2a agonist seems 
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Fig. 8. Effect of intrathecal administration of DPCPX on 
zymosan-induced visceral hyperalgesia. DPCPX, when injected 
intrathecally 5 minutes before the intrathecal administration of 
R-PIA, prevents the decrease in VMR to CRD by R-PIA.
DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; R-PIA, R(-)-N6- 
(2-phenylisopropyl)-adenosine; VMR, visceromotor response; 
CRD, colorectal distension.
not to reflect decreased pain perception. That is thought 
to be caused by motor weakness not by analgesic effect. 
Spinal administration of A1 agonist in this visceral pain 
model induced decrease in VMR without motor weakness. 
That means spinal A1 receptor has important role for an-
tinociception in visceral hyperalgesia. A recent study in-
sisted that adenosine A1 agonists inhibited both pain sen-
sation and muscle contraction, but nociceptive responses 
were inhibited at lower doses.23 However, in this study, 
even high doses of A1 receptor agonist given subcuta-
neously or intrathecally did not show motor weakness. 
Therefore, A1 receptor agonist can be a candidate of anti-
hyperalgesic agent for the treatment of visceral hyper-
algesia in functional gastrointestinal disorders. Strictly 
speaking, to confirm the selectivity of action on inflam-
mation-induced visceral hypersensitivity, the influence of 
these adenosine agonists has to be tested on basal viscer-
al sensitivity using intracolonic saline instillation before 
zymosan injection, and furthermore, experiments with a 
lower pressure of distention to determine a possible more 
selective action of adenosine analogues on components of 
colorectal hypersensitivity linked to inflammation to ob-
serve the role of low threshold receptors may be also 
needed. 
  In our study, we used adenosine analogues rather than 
adenosine itself. That is because adenosine, when given 
systemically, is so rapidly metabolized by endothelia cells 
(within 10 seconds). It is known that the potency of ad-
enosine agonists in suppressing sensory transmission is 
greatest in selective A1 agonist, and then both A1 & A2 
agonist, and selective A2 agonist in order.23 However, in 
this experiment, both A1 & A2 agonist induced more de-
crease in VMR to CRD than decrease in VMR by selective 
A1 agonist or A2 agonist alone. That means the amount of 
decrease in VMR by both A1 & A2 agonist was the sum-
mation of analgesic effect by A1 agonist and muscle relax-
ing effect by A2 agonist. That can be explained by the fact 
that the dorsal spinal cord contains both A1 and A2 
receptors.19-22 However, it is regretful that the role of en-
dogenous adenosine could not be evaluated due to lack of 
information but seemed to be trivial in the study because 
of its short duration of action compared to relatively long 
duration of balloon distention. The role of gut neural and 
non-neural A1, A2 or A3 receptors that might play a role 
in the subcutaneous hyperalgesic responses also could not 
be determined exactly in this protocol.
  The concentration of intrathecally administrated adeno-
sine to achieve analgesic effect was quite lower compared 
to that of systemically administrated adenosine. That 
means the main action site of adenosine is spinal cord. 
Usually adenosine A1 receptors are absent in the periph-
eral sensory terminal and they are present on the cell 
body of dorsal root ganglion cells and on the central ter-
minals of primary afferent neurons.24,25 Only under the 
specific circumstances, those receptors migrate to the pe-
ripheral aspect of this nerve. Meanwhile, adenosine-like 
immunoreactivity is exhibited by terminals in the sub-
stantia gelatinosa of the dorsal horn of the spinal cord 
where high levels of adenosine receptors are found in-
cluding A1 receptor.26 In addition adenosine, perhaps orig-
inating from ATP, is released from spinal synaptosomes.4 
All these findings indicate that adenosine may play a role 
in the modulation of nociceptive transmission at the spi-
nal level. 
  In conclusion, adenosine receptor agonists are anti-
hyperalgesic, but also produce motor weakness. Activa-
tion of the spinal A1 receptor, however, significantly at-
tenuates the VMR to CRD without producing motor 
weakness. 
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